Chinese bear bile company courts controversy with IPO plan
This article was originally published in Scrip
Executive Summary
A plan by a Chinese pharmaceutical company specialising in traditional medicines containing bear bile to seek a domestic stock listing has sparked strong opposition from animal welfare groups and members of the public.